Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
A Multi-centre, Double-blind, Placebo Controlled, Proof of Concept Study to Evaluate the Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis
Sponsor: Novartis Pharmaceuticals
Terminated
Trial was prematurely terminated due to enrollment challenges.
Other terminated trials from Novartis Pharmaceuticals
Other Dermatomyositis trials with similar outcome
Listed as NCT01148810, this PHASE2 trial focuses on Dermatomyositis and Polymyositis and remains terminated or withdrawn. Sponsored by Novartis Pharmaceuticals, it has been updated 9 times since 2010, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Dec 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Dec 2021 [monthly]
Terminated PHASE2
▶ Show 4 earlier versions
-
May 2019 — Jan 2021 [monthly]
Terminated PHASE2
-
Jun 2018 — May 2019 [monthly]
Terminated PHASE2
-
Feb 2017 — Jun 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Jun 2010
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Novartis Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .